vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.

UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $19.6M, roughly 1.8× STANDARD BIOTOOLS INC.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -177.4%, a 221.3% gap on every dollar of revenue. On growth, UNITY BANCORP INC posted the faster year-over-year revenue change (24.2% vs -11.5%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $-23.1M). Over the past eight quarters, UNITY BANCORP INC's revenue compounded faster (17.5% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.

LAB vs UNTY — Head-to-Head

Bigger by revenue
UNTY
UNTY
1.8× larger
UNTY
$35.3M
$19.6M
LAB
Growing faster (revenue YoY)
UNTY
UNTY
+35.6% gap
UNTY
24.2%
-11.5%
LAB
Higher net margin
UNTY
UNTY
221.3% more per $
UNTY
43.9%
-177.4%
LAB
More free cash flow
UNTY
UNTY
$67.4M more FCF
UNTY
$44.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
UNTY
UNTY
Annualised
UNTY
17.5%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
UNTY
UNTY
Revenue
$19.6M
$35.3M
Net Profit
$-34.7M
$15.5M
Gross Margin
48.5%
Operating Margin
-168.5%
55.8%
Net Margin
-177.4%
43.9%
Revenue YoY
-11.5%
24.2%
Net Profit YoY
-28.8%
34.5%
EPS (diluted)
$-0.09
$1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
UNTY
UNTY
Q4 25
$35.3M
Q3 25
$19.6M
$32.8M
Q2 25
$21.8M
$34.4M
Q1 25
$40.8M
$29.4M
Q4 24
$28.4M
Q3 24
$22.1M
$27.7M
Q2 24
$22.5M
$25.5M
Q1 24
$45.5M
$25.6M
Net Profit
LAB
LAB
UNTY
UNTY
Q4 25
$15.5M
Q3 25
$-34.7M
$14.4M
Q2 25
$-33.5M
$16.5M
Q1 25
$-26.0M
$11.6M
Q4 24
$11.5M
Q3 24
$-26.9M
$10.9M
Q2 24
$-45.7M
$9.5M
Q1 24
$-32.2M
$9.6M
Gross Margin
LAB
LAB
UNTY
UNTY
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
UNTY
UNTY
Q4 25
55.8%
Q3 25
-168.5%
57.5%
Q2 25
-118.1%
62.6%
Q1 25
-80.8%
52.6%
Q4 24
51.0%
Q3 24
-120.9%
52.7%
Q2 24
-134.5%
49.3%
Q1 24
-132.2%
50.0%
Net Margin
LAB
LAB
UNTY
UNTY
Q4 25
43.9%
Q3 25
-177.4%
43.8%
Q2 25
-153.7%
48.0%
Q1 25
-63.8%
39.5%
Q4 24
40.5%
Q3 24
-122.0%
39.4%
Q2 24
-203.3%
37.1%
Q1 24
-70.6%
37.5%
EPS (diluted)
LAB
LAB
UNTY
UNTY
Q4 25
$1.52
Q3 25
$-0.09
$1.41
Q2 25
$-0.09
$1.61
Q1 25
$-0.07
$1.13
Q4 24
$1.13
Q3 24
$-0.07
$1.07
Q2 24
$-0.12
$0.92
Q1 24
$-0.27
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
UNTY
UNTY
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$345.6M
Total Assets
$539.6M
$3.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
UNTY
UNTY
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
UNTY
UNTY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$230.8M
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
UNTY
UNTY
Q4 25
$345.6M
Q3 25
$399.7M
$334.0M
Q2 25
$424.5M
$319.8M
Q1 25
$454.6M
$306.1M
Q4 24
$295.6M
Q3 24
$489.3M
$284.3M
Q2 24
$510.3M
$273.4M
Q1 24
$577.3M
$266.8M
Total Assets
LAB
LAB
UNTY
UNTY
Q4 25
$3.0B
Q3 25
$539.6M
$2.9B
Q2 25
$557.0M
$2.9B
Q1 25
$579.6M
$2.8B
Q4 24
$2.7B
Q3 24
$681.5M
$2.6B
Q2 24
$708.7M
$2.6B
Q1 24
$777.7M
$2.6B
Debt / Equity
LAB
LAB
UNTY
UNTY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.78×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
UNTY
UNTY
Operating Cash FlowLast quarter
$-22.2M
$44.9M
Free Cash FlowOCF − Capex
$-23.1M
$44.3M
FCF MarginFCF / Revenue
-118.1%
125.7%
Capex IntensityCapex / Revenue
4.5%
1.6%
Cash ConversionOCF / Net Profit
2.90×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$81.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
UNTY
UNTY
Q4 25
$44.9M
Q3 25
$-22.2M
$45.5M
Q2 25
$-20.7M
$-25.3M
Q1 25
$-30.3M
$17.9M
Q4 24
$48.0M
Q3 24
$-27.9M
$17.7M
Q2 24
$-39.0M
$-8.4M
Q1 24
$-62.5M
$15.8M
Free Cash Flow
LAB
LAB
UNTY
UNTY
Q4 25
$44.3M
Q3 25
$-23.1M
$45.3M
Q2 25
$-22.6M
$-25.5M
Q1 25
$-35.3M
$17.6M
Q4 24
$47.3M
Q3 24
$-30.1M
$17.5M
Q2 24
$-41.0M
$-8.6M
Q1 24
$-63.3M
$15.7M
FCF Margin
LAB
LAB
UNTY
UNTY
Q4 25
125.7%
Q3 25
-118.1%
138.1%
Q2 25
-103.6%
-74.2%
Q1 25
-86.6%
59.9%
Q4 24
166.5%
Q3 24
-136.4%
63.3%
Q2 24
-182.2%
-33.7%
Q1 24
-138.9%
61.4%
Capex Intensity
LAB
LAB
UNTY
UNTY
Q4 25
1.6%
Q3 25
4.5%
0.7%
Q2 25
8.7%
0.5%
Q1 25
12.4%
1.0%
Q4 24
2.4%
Q3 24
10.2%
0.5%
Q2 24
8.6%
0.5%
Q1 24
1.7%
0.3%
Cash Conversion
LAB
LAB
UNTY
UNTY
Q4 25
2.90×
Q3 25
3.16×
Q2 25
-1.54×
Q1 25
1.54×
Q4 24
4.17×
Q3 24
1.62×
Q2 24
-0.89×
Q1 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

UNTY
UNTY

Segment breakdown not available.

Related Comparisons